Neurology; inflammation
Patient and mouse studies suggest inhibiting CCR5 could help treat stroke and traumatic brain injury (TBI). In stroke patients, the absence of a loss-of-function mutant CCR5 allele was associated with the severity of motor, sensory and cognitive impairments six months to one year after stroke. In a mouse model of stroke, injection into the pre-motor cortex of an shRNA targeting CCR5 encoded in an adeno-associated viral (AAV) vector or i.p. injection of the CCR5 antagonist Selzentry maraviroc increased ambulatory function and the number of dendritic spines and interhemispheric axon projections in the pre-motor cortex and decreased inflammation in the peri-infarct region of the cortex compared with empty vector or vehicle, respectively. In a mouse model of TBI, intrahippocampal injection of the shRNA targeting CCR5 encoded in an AAV vector or Selzentry decreased cognitive deficits. Next steps include testing Selzentry in stroke patients...
BCIQ Company Profiles
BCIQ Target Profiles